PLSE — Pulse Biosciences Share Price
0.000.00%
Last trade - 00:00- $617.97m
- $583.09m
- 34
- 13
- 73
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.35 | ||
| Price to Tang. Book | 18.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.23% | ||
| Return on Equity | -332.14% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.42 | 0.7 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Directors
- Robert Duggan NEC (77)
- Darrin Uecker PRE (55)
- Sandra Gardiner CFO (55)
- Edward Ebbers EVP (63)
- Mitchell Levinson DRC (60)
- Shelley Spray DRC
- Manmeet Soni IND (43)
- Richard van den Broek IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 18th, 2018
- Public Since
- May 18th, 2016
- No. of Shareholders
- 11
- No. of Employees
- 56
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 55,225,333
- Address
- 3957 Point Eden Way, HAYWARD, 94545-3720
- Web
- https://www.pulsebiosciences.com/
- Phone
- +1 5109064600
- Auditors
- Deloitte & Touche LLP
Upcoming Events for PLSE
Q3 2024 Pulse Biosciences Inc Earnings Release
Similar to PLSE
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
What is the Pulse Biosciences share price?
As of Today at 22:49 UTC, shares in Pulse Biosciences are trading at $10.74. This share price information is delayed by 15 minutes.
How has the Pulse Biosciences share price performed this year?
Shares in Pulse Biosciences last closed at $10.74 and the price had moved by +61.75% over the past 365 days. In terms of relative price strength the Pulse Biosciences share price has outperformed the S&P500 Index by +28.71% over the past year.
What are the analyst and broker recommendations for Pulse Biosciences?
The overall consensus recommendation for Pulse Biosciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Pulse Biosciences dividend yield?
Pulse Biosciences does not currently pay a dividend.
Does Pulse Biosciences pay a dividend?
Pulse Biosciences does not currently pay a dividend.
When does Pulse Biosciences next pay dividends?
Pulse Biosciences does not currently pay a dividend.
How do I buy Pulse Biosciences shares?
To buy shares in Pulse Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pulse Biosciences?
As of the previous close price of $10.74, shares in Pulse Biosciences had a market capitalisation of $593.12m.
Where are Pulse Biosciences shares listed?
Here are the trading details for Pulse Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PLSE
What kind of share is Pulse Biosciences?
Based on an overall assessment of its quality, value and momentum Pulse Biosciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pulse Biosciences share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Pulse Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pulse Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -25.88%.
As of the last closing price of $10.74, shares in Pulse Biosciences were trading +32.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pulse Biosciences PE Ratio?
The Pulse Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pulse Biosciences?
Pulse Biosciences' management team is headed by:
- Robert Duggan - NEC
- Darrin Uecker - PRE
- Sandra Gardiner - CFO
- Edward Ebbers - EVP
- Mitchell Levinson - DRC
- Shelley Spray - DRC
- Manmeet Soni - IND
- Richard van den Broek - IND